MedTrace Logo

A Study of Ruxolitinib in Pancreatic Cancer Patients

NCT02119663 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2018-02-13

Study results available
· View outcomes & findings →

Summary

This was to determine the efficacy, based upon overall survival, of ruxolitinib added to capecitabine for the treatment of metastatic pancreatic cancer.

Conditions

Interventions

DRUG

Ruxolitinib

5 mg tablets to be administered by mouth twice daily (BID)

DRUG

Placebo

5 mg matching placebo tablets to be administered by mouth twice daily (BID)

DRUG

Capecitabine

150 mg or 500 mg tablets to be administered by mouth twice daily (BID)

Sponsors & Collaborators

Principal Investigators

  • Fitzroy Dawkins, MD · Incyte Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2016-02-29
Completion
2016-10-31

Countries

  • United States
  • Austria
  • Chile
  • Colombia
  • Denmark
  • France
  • Ireland
  • Israel
  • Mexico
  • Netherlands
  • Portugal
  • Puerto Rico
  • Sweden
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02119663 on ClinicalTrials.gov